Hepatocellular carcinoma (HCC) is the most prevalent liver primary tumor and the third-most common cause of cancer death worldwide 1, 2 . Liver resection, transplantation or radiofrequency ablation are curative therapeutic options, useful in only less than 30% of the cases. In advanced HCC, administration of Sorafenib or other drugs provides survival benefit to unresectable HCC, yet without curing the disease 3 . Therefore, identification of new molecular strategies is urgently needed.
Various etiologies are associated with HCC, leading to significant heterogeneity in clinical outcome, histology, transcriptomic profile and mutational spectrum 4, 5, 6, 7, 8 .
Such heterogeneity can cause a variable response to therapeutic agents, as in mouse models with Ctnnb1-induced HCCs which show heterogeneous sensitivity to CTNNB1 (b-CATENIN) inhibitors 9 . Thus, designing novel therapeutic strategies against HCC requires not only the identification of inhibitors of individual tumorpromoting genes but also the characterization of the molecular networks in which those genes exert their functions.
Dedifferentiation of hepatic cells contributes to HCC progression 10, 11, 12 . In this context, poorly differentiated HCC develop as a result of forced induction of LIN28B, a RNA-binding protein which is repressed during normal hepatic cell differentiation.
LIN28B is re-expressed in a subset of human HCC's characterized by high serum levels of a-foetoprotein 13, 14 , thereby associating dedifferentiation, HCC progression and LIN28B expression 15 . In parallel, CTNNB1 is one of the most frequently mutated genes and drivers of HCC, with a mutation rate of 11%-37% 1 . Therefore, we here explore the possibility that HCC progression depends on a gene regulatory network (GRN) linking LIN28B-dependent dedifferentiation with CTNNB1 dysfunction.
Several approaches can be implemented to identify GRNs 16 . We here select a method which captures the dynamics and biological logic of the system, and identify a HCC-promoting GRN comprising several members connecting LIN28B with CTNNB1 via Let-7b, MYC, SMARCA4 (BRG1), TP53 and SOX9. We further investigate the system-level dynamics of the GRN with help of a quantitative mathematical model, which is calibrated and validated using quantitative mRNA and protein expression data from HCC cell lines, patient databanks and mouse models.
In silico simulation of the quantitative impact of a tumor-promoting gene on the expression of the other GRN members revealed the existence of distinct HCC cell states which may be at the origin of inter-tumoral heterogeneity.
Several components of the GRN identified here in HCC are instrumental in development of other cancers, and we provide evidence that the GRN is functional in several gastrointestinal cancers. Finally, we built a web-based platform which determines if the GRN is functional in individual HCC samples and allows in silico evaluation of potential anticancer strategies targeting the GRN.
Results

Identification of a gene regulatory network driving hepatocellular carcinoma.
We selected an approach in which GRN members must meet two criteria. First, their role in tumor-promotion must be validated by animal experimentation and/or highthroughput sequencing data from patients. Second, GRN members fitting the first criterion must be connected by direct or indirect functional links characterized by protein-protein and protein-DNA interactions, or epistatic relationship identified in loss-and gain-of function analyses.
By combining data from the literature, we first reconstituted a GRN comprising 7 cross-regulating components: the miRNA Let-7b, the RNA-binding protein LIN28B, the ATP-dependent helicase SMARCA4, and the transcription factors SOX9, MYC, CTNNB1 and TP53 ( Fig. 1a, left) : Let-7 is a tumor suppressor whose maturation is repressed by re-expression of LIN28B in cancer, including in HCC 17, 18, 19, 20 . LIN28B can cooperate with CTNNB1 to promote tumor development in mouse models of colorectal cancer 21 , it is stimulated by MYC and its overexpression is sufficient to induce HCC in mice 15 . In addition, MYC expression is stimulated by a CTNNB1/SMARCA4 complex, in which SMARCA4 is a chromatin regulator mutated in HCC 6, 7, 22 . Lastly, TP53 and MYC regulate each other 23 , and SOX9 is both a stimulator of CTNNB1 expression and target of Let-7b 24, 25 . Thus, this literaturebased GRN connects LIN28/Let-7, a key axis for cell differentiation, with CTNNB1 whose deregulation is often involved in HCC development. Within the Let-7 family, Let-7b is here selected since it is the most differentially expressed family member between normal and HCC samples 26 . The functional links in the GRN reflect direct or indirect regulations which were determined by transfection, gene inactivation, proteinprotein and protein-DNA interaction studies 8, 10, 11, 12 . When interactions have been identified in non-hepatic cells, we verified whether they also occurred in cultured HCC cell lines (see below).
Data from the The Cancer Genome Atlas (TCGA; Fig. 1a , right) show that expression of Let-7b is reduced in HCC as compared to adjacent non tumor liver tissue. This is consistent with the concomitant overexpression of LIN28B, a repressor of Let-7b. All other GRN components, except MYC, were increased in HCC. Further, a principal component analysis (PCA), which considers only the expression of the 7 GRN components in 50 non tumor controls and 369 HCCs revealed that non tumor tissue and HCC tumors clustered separately ( Fig. 1b and Supplementary Fig. 1a ).
We then considered the 100 HCC cases of the TCGA cohort with highest expression of a GRN component, and the 100 cases with lowest expression of the same component. We then verified whether the other GRN components were correlatively up-or down-regulated. Except for Let-7b, high expression of a component correlated with high expression of the other GRN components ( Supplementary Fig. 2a ). Also, in a PCA analysis the tumor samples with high expression of a GRN component clustered together and separate from the tumors with low expression and from the non tumor samples ( Supplementary Fig. 2b ). Together, these analyses suggest that the expression of the GRN components is correlated. Importantly, PCA investigating multiple targets of CTNNB1, Let-7b-3p and Let-7b-5p Table 1 ) also identified separate clusters for non tumor tissue and HCC tumors, indicating that the components of the GRN were not only misexpressed in HCC but also that they were actively regulating their targets ( Fig. 1c and Supplementary Fig. 1b ). Therefore, we considered that concomitant overexpression of the GRN components LIN28B, SMARCA4, SOX9, CTNNB1 and TP53, and downregulation of Let-7b was indicative of GRN activity.
Out of the 369 HCCs from the TCGA cohort whose GRN component expression had been analyzed by PCA we selected the 150 samples with the highest Dimension 1 to which CTNNB1, SMARCA4, SOX9, MYC and TP53 expression contribute the most, and out of the latter we selected the 100 samples with highest Dimension 2 to which LIN28B and Let-7b contribute the most ( Supplementary Fig. 1c ). These 100 samples were defined as displaying high GRN activity and were compared with the other 269 tumors, which were defined of low GRN activity, and with non tumor liver tissue (Fig.   1d ). The expression of the GRN components differed significantly between the tumors with low and high GRN activity. Moreover, the samples with high GRN activity displayed the highest expression of proliferation, embryonic and oncogenic markers, and the lowest levels of differentiation markers.
We next investigated if GRN activity in the 369 HCC patients of the TCGA cohort correlated with prognosis. Fig. 1e shows that the survival probability as a function of time was lower in the 100 HCC patients with high GRN activity than in the 269 HCC patients with low GRN activity. When performing the same analysis with individual components of the GRN, we found that expression of Let-7b, MYC and TP53 did not correlate with survival, while expression of CTNNB1, SOX9, SMARCA4 and LIN28B were inversely correlated with survival ( Supplementary Fig. 3 ). In this analysis of individual components, the cohort with high expression corresponded to the group of 100 patients with highest expression of the component, and the low expression cohort corresponded to the 269 other samples of the cohort. Together, the results indicate that the activity of the GRN as whole is a good marker of prognosis in HCC patients.
In conclusion, we have identified a GRN of functionally interacting partners which are misexpressed in HCC. The activity of the GRN, characterized by consistent and concomitant misexpression of its components and targets, correlates with proliferation, dedifferentiation and prognosis.
The gene regulatory network promotes a proliferative HCC phenotype but is not correlated with telomerase maintenance. HCC's are broadly divided in proliferative and nonproliferative classes 1, 27 . Dedifferention and high proliferation characterize the proliferative class and correlate with the GRN activity ( Fig. 1d ), suggesting that the GRN is associated with or promotes a proliferative phenotype of HCC's. This is further supported by our observation that GRN activity, defined as above, correlates with increased MET signaling, a pathway whose activation characterizes a subset of the proliferative HCC class 28 . Indeed, HCC's with low or high GRN activity and non tumor control samples from the TCGA cohort clustered separately in a PCA analysis when considering the expression of 110 HGF/MET target genes ( Fig. 2a and Supplementary Fig. 1d ). Moreover, to capture the tumors with highest HGF/MET target gene expression we selected 150 samples with the highest Dimension 1 and out of these we selected the 100 samples with highest Dimension 2 ( Supplementary Fig. 1e ). Those 100 tumor samples displayed increased expression of CTNNB1, SOX9, SMARCA4, MYC and TP53 as compared to the other 269 tumors ( Fig. 2b and Supplementary Fig. 1e ).
Earlier analyses correlated the transcriptome, genotype and phenotype of HCC patients and identified 6 patient subgroups numbered G1 to G6 29 . A predictor formula considered the expression of 16 genes to classify patients within one of the 6 subgroups, and, numerous genes were differentially expressed in the 6 subgroups 29 .
PCA analysis of the expression of a random selection of 216 differentially expressed genes or of the 16 predictor genes in non tumor tissue and HCC tumor of patients from the TCGA cohort revealed that tumors with high GRN activity cluster the farthest from the non tumor tissue ( Fig. 2c-d and Supplementary Fig. 1f -g). Among the 216 genes differentially expressed between the G1 to G6 subgroups, the 50 genes that contribute the most to the Dimension 1 in the PCA plot are all upregulated in the G1, G2 and G3 subgroups and are mainly involved in cell proliferation (listed in Supplementary Table 2 ), fitting with our observations that GRN activity may contribute to confer a transcriptomic profile typical of the proliferation class of HCC.
The G1, G2 and G3 subgroups are associated with poor differentiation, severe prognosis, and overexpression of genes regulating cell proliferation and DNA metabolism 29 . Together, the data support that the GRN is associated with and may promote a proliferative phenotype.
TERT promoter mutation are found in 60% of HCC's 30 . However, out of the 369 HCC samples of the TCGA cohort, the 100 samples with highest TERT expression did not consistently misexpress GRN components as compared to the 269 HCC samples with lower TERT expression levels ( Fig. 2e ). This suggests that GRN activity is disconnected from TERT overexpression-induced telomere maintenance. Supplementary Fig. 4a ).
Design of a mathematical model
Similarly, overexpression of constitutively active CTNNB1 S33Y and of SMARCA4 in
HepG2 or Huh7 cells validated the CTNNB1®LIN28B and CTNNB1®MYC and SMARCA4®MYC interactions in HCC ( Fig. 4b, Supplementary Fig. 4b-c ). Finally, transient transfection of Let-7b-5p mimic RNA significantly repressed LIN28B, MYC and SOX9, confirming the regulatory links in the GRN (Fig. 4c ).
The duration of the transient transfections in Fig. 4 (48h, 72h, 96h) reflected the minimal time-lapse required to monitor a significant change in TP53, LIN28B, MYC or SOX9 following overexpression of their respective stimulator or repressor. Therefore, both the level of protein induction and the timing required to observe a significant change in protein level were used to further calibrate the mathematical model of the GRN, while maintaining the quantitative calibration of all mRNA expression levels.
We then simulated the transient transfection conditions by increasing the transcription rate constants of MYC, CTNNB1 or Let-7b, starting at t = 0h ( Fig. 4a-c, right panels). The results showed that simulating a 10-fold increase in MYC -which mimics the observed 10-fold increase in transfected MYC protein-predicted a ~2-fold increase in LIN28B and TP53 after 72h; this predicted increase in LIN28B and TP53 matched closely the measured values (compare black and orange bars in Fig. 4a ).
Similarly, simulating an 8-fold increase in CTNNB1 S33Y predicted a ~3-and 11-fold induction of LIN28B and MYC after 48h; these inductions again matched closely the measured 4-and 9-fold induction of LIN28B and MYC, following an 8-fold increase in transfected CTNNB1 S33Y (Fig. 4b) . Moreover, following a simulated 8-fold induction of Let-7b the model reproduced quantitatively the experimentally measured impact of Let-7b induction on LIN28B, MYC, and SOX9 ( Fig. 4c ). Finally, Let-7b induction in HuH7 cells did not affect CTNNB1 expression, which fitted with the model simulation ( Fig. 4c ). We concluded that the calibrated mathematical model faithfully recapitulates the expression of GRN components.
Validation of the mathematical model. To validate the model, we first challenged it by predicting the impact of a stabilizing CTNNB1 mutation on LIN28B and Let-7b expression and compared the prediction with values from the TCGA database. To this end we first partitioned the HCC samples of the TCGA database in two cohorts characterized by the presence or absence of stabilizing CTNNB1 mutation, the most frequent CTNNB1 mutations in the cohort being missense mutations in exon 3. This revealed that CTNNB1 mRNA levels were higher in the presence of a mutation (Fig.   5a , left). Therefore, to simulate CTNNB1 stabilization in the model we increased the CTNNB1 mRNA synthesis rate (Supplementary information), increased the activation rate of the inactive (complexed) CTNNB1 form, and decreased the inactivation rate of the active (stabilized) form. Under these conditions, when CTNNB1 mRNA values from the mutated and non-mutated samples were introduced in the model (Fig. 5a , orange bars), it faithfully predicted the reduction in Let-7b observed in non-mutated HCC samples as well as the slightly larger decrease of Let-7b seen in HCC samples with CTNNB1 mutation. Also, the model predicted the increased LIN28B expression in HCC which was similar whether CTNNB1 was mutated or not (compare orange and black bars in Fig. 5a ).
A second validation was obtained by considering previous results from a mouse model of MYC-induced liver cancer 15 . We simulated a 4000-fold increase in MYC mRNA, which corresponds to the experimental induction of Myc in mice. Our simulation predicted a MYC-induced 7000-fold overexpression of Lin28b mRNA and a 0.4-fold reduction in Let-7b. This prediction fitted well with the experimentallymeasured induction of Lin28b and reduction of Let-7b (Fig. 5b) .
Third, as a proof of concept that the mathematical model can predict the impact of a pharmacological inhibitor of a GRN component, we simulated the inhibition of LIN28B in HCC: simulating 60 % inhibition of LIN28B protein predicted an increase in Let-7b and a decrease in SOX9 and MYC protein; CTNNB1 remained unaffected (Fig. 5c ). Let-7b was associated with low CTNNB1 mRNA, and vice versa (Fig. 5d, left) . The system exhibits a reversible bistable switch from high to low levels of Let-7b, at supraphysiological levels of CTNNB1 mRNA. Green dots in Fig. 5d (left) represent measured Let-7b/CTNNB1 mRNA values in normal samples from the TGCA cohort.
However, simulating Let-7b as a function of CTNNB1 mRNA in HCC conditions revealed an irreversible bistable switch occuring at low CTNNB1 mRNA levels (Fig.   5e , left). Indeed, rising CTNNB1 mRNA from low to supraphysiological levels in HCC would induce a switch from high to low Let-7 expression, but reverting from supraphysiological CTNNB1 to low CTNNB1 levels would not allow to restore high (Fig. 5d , right, black dots). Modelling a HCC cell population with the same % of parameter variation generated a distribution of Let-7b/CTNNB1 values similar to that seen in HCC patients and cell lines (Fig. 5e, right) , indicating that the model accounts for the sample's heterogeneity.
We next analyzed the robustness of the bistable switch dynamics in normal and HCC conditions towards variation of parameter values. We plotted the steady-state levels of Let-7b as a function of CTNNB1 mRNA levels in the presence of a two-fold increase or decrease of each parameter value ( Supplementary Figs. 5 and 6 ). In normal condition, i.e. high Let-7b and low CTNNB1 mRNA, the model is very robust towards 2-fold parameter variation since high Let-7b levels are maintained regardless of parameter variations ( Supplementary Fig. 5 ). In contrast, in HCC conditions the irreversible bistable switch dynamics can be lost following parameter variations, and only the bottom stable steady state of the bistable switch is maintained ( Supplementary Fig. 6 ). Thus, the tumor state is more sensitive towards parameter variations than the normal state. This is expected to be reflected in patient samples by increased heterogeneity in expression of the GRN components, as observed in (Fig. 6a, Supplementary Fig. 7) . where Let-7c is strongly repressed. The other cancer types did not show a consistent increase in GRN components, suggesting that the GRN does not display tumorpromoting activity in these tumors.
Tu and coworkers developed a mouse model of colorectal cancer with similar gene expression pattern as in human cancer 21 , which offered the opportunity to validate the mathematical model in this cancer type. The published mouse data showed that induction of Lin28b for 6 months triggered cell proliferation, downregulation of Let-7 and upregulation of Sox9, the latter being illustrated by immunostaining 21 . The subsequent removal of Lin28b for 2 months partially restored the expression of Let-7 and proliferation markers. As in the experiments 21 , the mathematical model predicts that a 6-month induction of LIN28B leads to downregulation of Let-7b and upregulation of SOX9, and that those expression levels partially revert to near normal values 2 months after LIN28 removal (Fig. 6b) , thereby validating the GRN model in colorectal cancer. The mathematical model also shows that the expression of MYC ( Fig. 6b ) and CTNNB1 mRNAs (not shown) is not affected by LIN28B induction, which fits well with the observations 21 .
Discussion
The pattern of genetic and epigenetic alterations is heterogeneous in HCC.
Therefore, to understand the mechanisms of disease progression and design therapeutic strategies, there is a need to identify the functionality and the dynamics of GRNs driving HCC in individual samples 4, 29, 33 . Here we identified a GRN consisting of functionally-interacting components and which is activated in HCCs and gastrointestinal tumors. The GRN combines CTNNB1, SMARCA4, SOX9, LIN28B, Let-7b, TP53 and MYC, which are misexpressed and/or mutated in HCC. MYC expression is not strongly affected in the HCC cohort but it is higher in tumors with high GRN activity than in tumors with low GRN activity, and plays a role in mouse models of HCC 15 .
Since the mathematical model resorts to two sets of parameters, one for normal condition and one for tumors and cell lines, it does not account for the dynamics of transition between normal and HCC states. Indeed, to properly calibrate the model on the mRNA expression levels, the transcription rates of LIN28B, SOX9, mutant TP53, CTNNB1 and SMARCA4 had to be increased in the HCC conditions (see 'tumor' parameter in Supplementary Tables 4 and 5 ). The need to increase these parameters indicates that the interactions between GRN components are not sufficient to account for the normal-to-HCC transition. The model parameters implicitly integrate the impact of external regulators of the GRN. Yet, the modelling strategy cannot integrate the full spectrum of regulations, and a number of regulators might not be known. Since modelling the transition from normal to HCC requires adaptation of the transcription rates of LIN28B, SOX9, mutant TP53, CTNNB1 and SMARCA4, we suggest that the mechanisms controlling the expression of those genes warrant further investigation.
PCA analysis based on the expression of GRN components allowed us to define subclasses of patients. Molecular classifications of HCC's identified proliferative
versus non proliferative classes, and another approach correlated the transcriptome, genotype and phenotype of HCC patients to subdivide patients in 6 subgroups called G1 to G6 29 . Our observations suggest that GRN activity may contribute to confer a transcriptomic profile typical of the proliferative class of HCC. Consistently, the GRN is most activated in the G1, G2 and G3 subgroups which are associated with poor differentiation, severe prognosis, and overexpression of genes regulating cell proliferation 29 . The targets of CTNNB1 are heterogeneous as it induces progenitortype genes in tumor cells such as cyclin-D1 or VEGF-A, but also regulates expression of antioxidant, pro-survival and pro-hepatocyte differentiation genes in normal hepatocytes 34 . The G5 and G6 HCC subgroups are associated with activation of CTNNB1 targets typical for mature hepatocytes, whereas the G1, G2, and G3 subgroups show predominant activation of progenitor-type targets.
Interestingly, high GRN activation is associated with high expression of progenitortype CTNNB1 targets ( Supplementary Fig. 8 ).
The structure of the GRN comprises several positive feedback loops which are at the origin of reversible and irreversible bistable switches. Bistable switches have been identified in multiple molecular regulatory networks involved in differentiation, signaling or proliferation pathways 35, 36, 37, 38 . However, our quantitative modelling approach identified the first irreversible bistable switch involved in a specific subset of HCC tumors. It sheds light on the nature of a dynamical mechanism which can be a source of heterogeneity among HCC samples. In addition, the identification of irreversible states in HCC provides evidence that targeting specific GRN components using drugs might be therapeutically ineffective, given that the cancer cell is in a locked state with regard to the function of the target. Also, our comparison of patient tumors and cultured HCC lines (Fig. 5e ) indicates that cell lines may be in a state distinct from that of tumors with regard to the function of the GRN. This raises the need for caution when testing the efficacy of drugs in cultured cells. To facilitate the analysis of the GRN, we set up a user-friendly web-platform allowing to check GRN activity in HCC and in gastrointestinal tumors. This platforms also presents a graphical user interface that integrates the expression levels of the GRN components of new tumor samples, and which implements the mathematical model to test which component of the network is the best target to modulate the network dynamics (http://biomodelling.eu/apps.html). We anticipate that identification and modelling of a set of GRNs consisting each of functionally-interacting components will significantly contribute to provide a global picture of tumor-promoting gene function in HCC. Our study presents the concept of tools that help in the design of bespoke therapies for treating each patient's specific cancer. Matlab. PCA analysis was performed with FactoMineR (R package) 39 .
Methods
RNASeq and miRNASeq data. RNASeq and miRNA Seq data of patient cohorts were from TCGA database (http://firebrowse.org/). For each cohort, we converted the "scaled_estimate" in the "illuminahiseq_rnaseqv2_unc_edu_Level_3_RSEM_genes" file into TPM by multiplying by 10 6 .
Plasmids and microRNAs. Plasmids pCDNA3.1, pcDNA3-MYC, pCl-neo β-Catenin (CTNNB1 S33Y ), pBABE-BRG1 were from Thermo Fisher Scientific (Waltham, MA, USA), Wafik El-Deiry (Addgene plasmid # 16011) 40 , Bert Vogelstein (Addgene plasmid # 16519) 41 and Robert Kingston (Addgene plasmid # 1959) 42 respectively. 
RNA extraction and analysis
Total RNA was isolated from Huh7 cultured cells, in the presence or absence of LIN28 inhibitor for 6 days, using Trizol (#1029602, Invitrogen, Life technologies). cluster separately in a PCA analysis based on the expression of 110 HGF/MET target genes (see Table 1 in Ref. 28 ). Within the HCC samples, those with high GRN activity (red; GRN activity defined as in Fig. 1d) Supplementary Fig. 1e ). overexpression of CTNNB1 S33Y (for 0 < t < 48h V S1CTNNB1 increases from 0.0015 to 0.04 while k ACTNNB varies from 0.05 to 10 and k ICTNNB from 10 to 0.1) and (c) overexpression of Let-7b (for 0 < t < 96h, V S1LET7 increases from 0.01 to 0.1). The right panels in a-c show the simulated temporal evolution, with the appropriate time scale, of the GRN proteins following MYC, CTNNB1 S33Y , or Let-7b mimic transfection. Tables 4 and 7 for parameter values and initial conditions for the variables used in the model. 
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